Neurokinin-1 Receptor Antagonists for Chemotherapy-Induced Nausea and Vomiting: A Systematic Review

Multicenter, phase II, placebo-controlled, double-blind, randomized study of aprepitant in Japanese patients receiving high-dose cisplatin

(2010) Toshiaki Takahashi et al.   CANCER SCIENCE

Meta-analysis for rare events

(2010) Tianxi Cai et al.   STATISTICS IN MEDICINE

Randomized, double-blind, dose-ranging trial of the oral neurokinin-1 receptor antagonist casopitant mesylate for the prevention of cisplatin-induced nausea and vomiting

(2009) F. Roila et al.   ANNALS OF ONCOLOGY

Phase 2 trial results with the novel neurokinin-1 receptor antagonist casopitant in combination with ondansetron and dexamethasone for the prevention of chemotherapy-induced nausea and vomiting in cancer patients receiving moderately emetogenic chemotherapy

(2009) Wichit Arpornwirat et al.   CANCER

Phase III Trial of Casopitant, a Novel Neurokinin-1 Receptor Antagonist, for the Prevention of Nausea and Vomiting in Patients Receiving Moderately Emetogenic Chemotherapy

(2009) Jørn Herrstedt et al.   JOURNAL OF CLINICAL ONCOLOGY

Efficacy and safety of casopitant mesylate, a neurokinin 1 (NK1)-receptor antagonist, in prevention of chemotherapy-induced nausea and vomiting in patients receiving cisplatin-based highly emetogenic chemotherapy: a randomised, double-blind, placebo-controlled trial

(2009) Steven M Grunberg et al.   LANCET ONCOLOGY

Aprepitant for the prevention of chemotherapy-induced nausea and vomiting associated with a broad range of moderately emetogenic chemotherapies and tumor types: a randomized, double-blind study

(2009) Bernardo L. Rapoport et al.   SUPPORTIVE CARE IN CANCER

Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement

(2009) David Moher et al.   PLOS MEDICINE

Chemotherapy-induced nausea and vomiting: ESMO Clinical Recommendations for prophylaxis

(2008) J. Herrstedt et al.   ANNALS OF ONCOLOGY

A randomized study of aprepitant, ondansetron and dexamethasone for chemotherapy-induced nausea and vomiting in Chinese breast cancer patients receiving moderately emetogenic chemotherapy

(2008) Winnie Yeo et al.   BREAST CANCER RESEARCH AND TREATMENT

Randomized, placebo-controlled, pilot study evaluating aprepitant single dose plus palonosetron and dexamethasone for the prevention of acute and delayed chemotherapy-induced nausea and vomiting

(2008) Jon D. Herrington et al.   CANCER

Aprepitant in adolescent patients for prevention of chemotherapy-induced nausea and vomiting: A randomized, double-blind, placebo-controlled study of efficacy and tolerability

(2008) Lia Gore et al.   PEDIATRIC BLOOD & CANCER

The Impact of Substance P Signalling on the Development of Experimental Staphylococcal Sepsis and Arthritis

(2008) M. Verdrengh et al.   SCANDINAVIAN JOURNAL OF IMMUNOLOGY